AMDL To Begin Trading On the American Stock Exchange On September 20, 2001 Under Symbol ADL.Business Editors & Health/Medical Writers TUSTIN, Calif.--(BW HealthWire)--Sept. 20, 2001 AMDL AMDL Abstract Module Description Language AMDL Approximate Minimum Description Length , Inc., developer and marketer of tests for the early detection of cancer and other serious diseases, announced today that shares of its common stock will begin trading on the American Stock Exchange American Stock Exchange (AMEX) Stock exchange in the U.S. Originally known as “the Curb,” it began as an outdoor marketplace in New York City c. 1850. It moved indoors to its present location in the Wall Street area in 1921. , under the symbol ADL, at the opening of the market on September 20, 2001. AMDL's common stock formerly traded on the OTC Bulletin Board OTC Bulletin Board An electronic quotation listing of the bid and asked prices of OTC stocks that do not meet the requirements to be listed on the NASDAQ stock-listing system. under the symbol AMDD AMDD Agile Model-Driven Development (software development) AMDD Assembly and Maintenance Definition Document AMDD Air and Missile Defense Division AMDD Aggressive Model-Driven Design . The company's CUSIP number remains the same and there is no need for shareholders to exchange their certificates or those held in Street name. The American Stock Exchange is the nation's second largest floor-based exchange. It lists approximately 750 companies and conducts trading through an advanced centralized specialist system. Cohen cohen or kohen (Hebrew: “priest”) Jewish priest descended from Zadok (a descendant of Aaron), priest at the First Temple of Jerusalem. The biblical priesthood was hereditary and male. Specialist LLC will be the specialist for AMDL. "Our listing on the AMEX AMEX See: American Stock Exchange is welcome recognition of our progress as we expand the commercial distribution of our groundbreaking technologies and products," said Gary L. Dreher, AMDL President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. . About AMDL AMDL, Inc., headquartered in Tustin, California, is the inventor and developer of the DR-70(TM) cancer test, a non-invasive blood test which has demonstrated its ability to detect the presence in humans of up to 13 cancers simultaneously 84 percent of the time overall. Clinical studies have been conducted in China, Canada, Taiwan and Turkey. Cancers that can be detected by the test are lung, colon, breast, stomach, liver, rectum, ovary, cervix, esophagus, thyroid, pancreas, trophoblast trophoblast /tro·pho·blast/ (tro´fo-blast) the peripheral cells of the blastocyst, which attach the blastocyst to the uterine wall and become the placenta and the membranes that nourish and protect the developing organism. and malignant lymphoma. The DR-70 is a non-invasive test that can detect cancer in these various organs using a single tube of blood, eliminating the need for costly, multiple tests. More information about AMDL and its additional products can be obtained at www.amdlcorporate.com. Forward-Looking Statements: Statements in this press release may constitute forward-looking statements and are subject to numerous risks and uncertainties, including the failure to complete successfully the development of new or enhanced products, the Company's future capital needs, the lack of market demand for any new or enhanced products the Company may develop, any actions by the Company's partners that may be adverse to the Company, the success of competitive products, other economic factors affecting the Company and its markets, and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission. The actual results may differ materially from those contained in this press release. The Company disclaims any obligation to update any statements in this press release. |
|
||||||||||||||||

Printer friendly
Cite/link
Email
Feedback
Reader Opinion